Previous Close | 214.55 |
Open | 212.30 |
Bid | 211.20 x N/A |
Ask | 222.00 x N/A |
Day's Range | 212.30 - 218.40 |
52 Week Range | 212.30 - 298.40 |
Volume | |
Avg. Volume | 916,406 |
Market Cap | 183.8B |
Beta (5Y Monthly) | 0.18 |
PE Ratio (TTM) | 16.66 |
EPS (TTM) | 13.00 |
Earnings Date | Jul 25, 2024 |
Forward Dividend & Yield | 9.50 (3.99%) |
Ex-Dividend Date | Mar 16, 2023 |
1y Target Est | N/A |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Q1 2024 Sarepta Therapeutics Inc Earnings Call
CQDM is proud to announce the funding of a collaborative research project to identify biomarkers and therapeutic solutions for diabetic kidney disease (DKD), one of the leading causes of kidney failure. This project, with a total value of over $9.4M, is made possible thanks to a $1.5M grant from the Quebec government (MEIE) awarded by CQDM, as well as a $2.4M financial contribution from Hoffmann-La Roche Limited (Roche) and another $2.8M from the Jewish General Hospital Foundation, and nearly $2